Short answer
Oruka Therapeutics, Inc. (ORKA) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Phase 2b EVERLAST-B Week 16 results announced for ORKA-001 in moderate-to-severe plaque psoriasis.
Oruka Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Phase 2b EVERLAST-B Week 16 results announced for ORKA-001 in moderate-to-severe plaque psoriasis
- ORKA-001: investigational half-life extended IL-23p19 monoclonal antibody
- Results presentation and press release publicly available October 26, 2026
- Conference call and webcast scheduled October 26, 2026 at 8:00 a.m. Eastern Time
Item 8.01 · Other Events
- ORKA-001 achieved PASI 100 in 61% of high-dose patients versus 0% placebo at Week 16, primary endpoint significant at p<0.0001
- High-dose efficacy: PASI 90 86% and IGA 0/1 86%, supporting potential competitiveness in moderate-to-severe psoriasis
- Safety favorable: treatment-emergent adverse events 39% high-dose versus 43% placebo, with no serious events in the high-dose group
- Phase 3 trials planned for the first half of 2027, subject to regulatory interactions, advancing ORKA-001 toward pivotal testing
- $1.1 billion in cash, equivalents and marketable securities as of June 30, 2026, expected to fund operations through anticipated BLA filing
Item EX-99.1 · Exhibit EX-99.1
- ORKA-001 high-dose group achieved PASI 100 in 61% and PASI 90 in 86% at Week 16, versus 0% placebo
- Efficacy closely matched EVERLAST-A, strengthening confidence in reproducibility across Phase 2 trials
- High-dose safety favorable: 39% TEAEs versus 43% placebo, with no serious TEAEs or injection-site reactions
- Phase 3 psoriasis trials planned for 1H 2027, pending regulatory discussions
- Key catalysts: EVERLAST-A 52-week results in December 2026 and ORKA-002 16-week results in 1Q 2027
Item EX-99.2 · Exhibit EX-99.2
- ORKA-001 EVERLAST-B met primary endpoint: 61% PASI 100 at Week 16 with 600 mg versus 0% placebo, supporting Phase 3 selection
- PASI 90 reached 86% at Week 16, reinforcing efficacy across two independent trials, though cross-trial comparisons are not head-to-head
- Safety remained consistent with the IL-23 class, with 2% serious TEAEs and 1% discontinuation due to TEAEs among 140 treated patients
- Phase 3 initiation planned for 1H 2027, with Week 52 data expected December 2026 to assess annual-dosing potential
- Strong cash position exceeding $1B, as of June 30, 2026, reportedly funds runway through ORKA-001 BLA filing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oruka Therapeutics, Inc. 8-K filings
Get the next ORKA 8-K as it lands
Follow ORKA for push alerts, or ask the research agent what this filing means.